Prescreening rate of Phase 2b ReTain trial triggers clinical development milestone payment in September Potentially registrational trial is targeting enrollment of approximately 500 participants with ...

Mutuum Finance (MUTM) has entered a narrow phase of its roadmap where timing, visibility, and supply dynamics begin to overlap. Projects often reach moments where progress is no longer theoretical but ...

Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in ...

Xenon Pharmaceuticals Inc. Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026. Five additional Phase 3 azetu ...

Management stated, "Final data and conclusions from both cohorts [of the ASCEND trial] are anticipated for the first quarter of 2026." Nisco projected, "the company projects that available funds will ...

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) surpassed the 600-patient ...

PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion ...